Formulation and evaluation of bi-layer tablet of metoclopramide hydrochloride and ibuprofen.
The aim of this study was to prepare bi-layer tablet of Metoclopramide Hydrochloride (MTH) and Ibuprofen (IB) for the effective treatment of migraine. MTH and IB were formulated as immediate and sustained release layer respectively. MTH was formulated as immediate release layer by using various disintegrants like Ac-Di-Sol, Polyplasdone XL, Explotab, Agar and Gellan Gum. Treated form of gellan gum and agar was prepared and compared for their disintegrant efficiency with other disintegrants. IB was formulated as sustained release layer using hydrophilic matrix (hydroxypropylmethylcellulose [HPMC K(4)M]). The effect of concentration of hydrophilic matrix (HPMC K(4)M), binder (polyvinylpyrollidone [PVP K(30)]) and buffer (sodium bicarbonate) on IB release was studied. The dissolution study of sustained release layer showed that an increasing amount of HPMC or PVP K(30) results in reduced IB release. The inclusion of buffer (sodium bicarbonate) enhanced the release of IB from sustained release layer. The rational for formulation of bi-layer tablet of these two drugs in combination was (1) MTH increases the absorption of acidic non-steroidal anti-inflammatory drug (NSAID) by increasing gastric motility. So sequential release of MTH (as immediate release) and IB (as sustained release) was suitable for treatment of migraine. (2) MTH was degraded when prolonged contact with acidic NSAID. Bi-layer tablet was suitable for preventing direct contact of these two drugs and thus to maximize the efficacy of combination of two drugs for migraine.
Shiyani
Bhavesh
B
Pharmaceutics Department, R.C. Patel College of Pharmacy, Near Karwand Naka, Shirpur, Dhule, 425405 Maharashtra, India.
Gattani
Surendra
S
Surana
Sanjay
S
D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000138:chemical synthesis / Q000493:pharmacokinetics; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical / Q000379:methods; D007052:Ibuprofen / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D008787:Metoclopramide / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D013607:Tablets
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D013607:Tablets; D008787:Metoclopramide; D007052:Ibuprofen